Why the study?
Does Qiliqiangxin inhibit cardiac hypertrophy, remodeling, and dysfunction in a mouse model of pressure overload compared to losartan?
Population
C57BL/6 mice undergoing transverse aorta constriction (pressure overload model)
Comparison
Qiliqiangxin (QL) 0.6 mg/kg/d vs Losartan 13.4 mg/kg/d
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
Hypothesis-generating for Qiliqiangxin in pressure-overload models; leaves open clinical translation of ErbB effects.
Does Qiliqiangxin inhibit cardiac hypertrophy, remodeling, and dysfunction in a mouse model of pressure overload compared to losartan?
In a mouse model of pressure overload, Qiliqiangxin ameliorated cardiac remodeling and function comparably to losartan, while uniquely promoting cardiomyocyte proliferation via ErbB receptor activation.
Zou et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: